argenx Announces Plan To Continue The Development Of Efgartigimod Primary Sjogren's Disease
Portfolio Pulse from Benzinga Newsdesk
argenx has announced its decision to continue the development of Efgartigimod for the treatment of primary Sjogren's disease, based on positive results from the RHO study. The decision was influenced by the drug's favorable safety profile and consistent efficacy and biomarker measures.
March 27, 2024 | 7:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
argenx's decision to continue Efgartigimod's development for primary Sjogren's disease is based on positive RHO study outcomes, highlighting a favorable safety profile and consistent efficacy.
The continuation of Efgartigimod's development for primary Sjogren's disease is a significant positive development for argenx. The decision, based on favorable study results, indicates potential for future regulatory approval and market expansion. This could lead to increased investor confidence and a positive impact on ARGX's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100